DSIP, short for delta sleep-inducing peptide, hasn't been shown to treat sleep apnea, repeated breathing interruptions during sleep. It has no established role as a replacement for CPAP, a machine that keeps the airway open with air pressure.
Claims about DSIP and sleep apnea need to show what happens to breathing. Falling asleep more easily is different from breathing normally through the night.
DSIP and sleep apnea start with different questions
Three complaints can sound alike when someone says they slept badly:
- Insomnia means difficulty falling or staying asleep despite having the opportunity to sleep.
- Daytime sleepiness means a tendency to doze off while awake. It isn't quite the same as feeling drained.
- Obstructive sleep apnea means the upper airway repeatedly narrows or closes during sleep, reducing or stopping airflow.
These problems can overlap. Someone can lie awake for long stretches and also have breathing interruptions after falling asleep. Feeling sleepy doesn't identify the cause.
The National Heart, Lung, and Blood Institute's sleep apnea guide explains why snoring, gasping and daytime sleepiness belong in a clinical conversation. Those observations raise questions; they don't diagnose apnea on their own.
The DSIP versus melatonin comparison addresses a different sleep question. Comparing sleep-related substances cannot establish whether either one keeps an obstructed airway open.
What the DSIP studies actually measured
DSIP is a peptide, a short chain of protein building blocks. Its name can make the evidence sound more settled than it is.
In a 1992 study by Bes and colleagues in Neuropsychobiology, 16 people with chronic insomnia received DSIP or placebo, an inactive comparison. Neither participants nor researchers knew who received which treatment.
Some recorded sleep measures favored DSIP, but the effects were weak. Participants didn't rate their sleep as better. Those findings concern sleep quality and timing; they don't establish fewer breathing interruptions or less need for CPAP. Our DSIP benefits guide covers the broader sleep evidence.
Has DSIP been studied in people with apnea?
There is also research involving people with apnea. A 1995 study by Vgontzas and colleagues in Peptides measured DSIP-like signals in blood. It found no significant differences between the apnea groups and comparison groups without apnea.
That was a measurement study, not a trial of giving DSIP for breathing problems. A blood level can't tell you whether a DSIP prescription would help apnea.
How a clinician checks for sleep apnea
The American Academy of Sleep Medicine's 2017 diagnostic guideline calls for a sleep evaluation and testing. A questionnaire alone cannot diagnose apnea.
For adults without complicating medical conditions whose symptoms point to a higher risk of moderate to severe apnea, the guideline accepts either a laboratory study or a technically adequate home sleep apnea test. Others need polysomnography, a laboratory study recording sleep and breathing. Severe insomnia is one reason the guideline favors laboratory testing.
A single negative home test doesn't rule apnea out. The guideline strongly recommends laboratory testing when a home result is negative, unclear or technically inadequate.
Can DSIP replace CPAP?
DSIP has not been shown to replace CPAP. Evidence about falling asleep or spending more time asleep cannot establish that the airway stayed open.
A treatment study would need to assess breathing interruptions, oxygen levels and other relevant outcomes in people with apnea. The old insomnia results don't provide that comparison.
The AASM's 2019 treatment guideline recommends follow-up that checks treatment effectiveness and addresses problems using the equipment. Mask discomfort or continued tiredness can become questions for that review, rather than evidence that a peptide is a substitute.
As of November 5, 2026, the day this article was written, an October 2026 European guideline in European Respiratory Journal strongly recommends CPAP for adults with apnea and excessive daytime sleepiness. Its recommendations are more conditional in other groups, meaning the balance needs an individual discussion. This is guidance about treating diagnosed apnea, a different question from the older DSIP insomnia experiments.
Safety with apnea is a separate question
There isn't enough direct evidence to say whether DSIP improves or worsens obstructed breathing. That uncertainty also prevents treating its name as reassurance about safety during sleep.
The DSIP evidence review from the Food and Drug Administration (FDA) describes preliminary, inconsistent sleep findings. It also finds safety insufficiently characterized. Small studies in other settings cannot establish safety for someone with untreated apnea.
The DSIP side effects guide covers reported harms. A clinician also considers current medicines, alcohol use and breathing history when weighing a sleep-related request.
DSIP's FDA status and the HHS notice
As of November 5, 2026, the day this article was written, the Department of Health and Human Services (HHS) has published an October 30 notice describing a nonbinding draft policy on preparing prescription medicines with certain peptides. DSIP is absent from its six-peptide Appendix A; our HHS peptide policy explainer covers all ten conditions.
Compounded DSIP is prepared by a pharmacy for an individual prescription. It is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor.
Neither a policy document nor a prescription adds evidence that DSIP treats an obstructed airway.
What a sleep-focused review can clarify
A useful review distinguishes difficulty sleeping from repeated breathing interruptions and daytime dozing. Prior sleep-study results, current apnea treatment and problems using it help a clinician understand what remains unresolved.
At Promise, a licensed provider reviews every request, and not everyone qualifies. If a prescription is written, a licensed U.S. compounding pharmacy prepares and dispenses the medication. The prescriber sets any treatment plan.
Existing apnea care remains part of that conversation when a peptide is being considered. Feeling more rested and having breathing controlled are separate outcomes that follow-up needs to account for.





